SCHEMBL810189

SCHEMBL810189

CC(Oc1ccc(Sc2ccc(O)cc2)c(N)c1)c1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.50
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 3/20 0.50
HPGD P15428 3/20 0.50
AGBL2 Q5U5Z8 1/20 0.40
LMNA P02545 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PPARA Q07869 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
F9 P00740 1/20 0.36
SLC6A2 P23975 3/20 0.35
SLC6A4 P31645 3/20 0.35
TP53 P04637 2/20 0.35
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP2D6 P10635 1/20 0.34
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL810621 0.88 CYP2D6 (0.43) MAPTALDH1A1KDM4EHPGDLMNA
SCHEMBL810257 0.87 MAPT (0.42) MAPTALDH1A1KDM4EHPGDAGBL2
SCHEMBL811477 0.81 MAPT (0.36) MAPTALDH1A1KDM4EHPGDLMNA
SCHEMBL810574 0.77 MAOB (0.49) MAPTALDH1A1KDM4EHPGDLMNA
SCHEMBL5069013 0.75 KDM4E (0.45) MAPTALDH1A1KDM4EHPGDSLC6A2
SCHEMBL13577140 0.72 PPARA (0.40) ALDH1A1HPGDLMNAPPARAF9
SCHEMBL811162 0.71 CACNA1C (0.51) MAPTALDH1A1KDM4EHPGDAGBL2
SCHEMBL810264 0.70 SLC6A2 (0.43) MAPTALDH1A1KDM4EHPGDAGBL2
SCHEMBL809916 0.70 MAPT (0.46) MAPTALDH1A1LMNANPSR1MEN1
SCHEMBL1454650 0.69 NR1H2 (0.52) MAPTALDH1A1KDM4EHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
EP-1971611-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-09-24 EP disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 MAPT 1347/4885ALDH1A1 2723/4885KDM4E 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.